Navigation Links
ClearWay Minnesota(SM) to Share Stories of Real Minnesotans Who Used QUITPLAN(R) Services During Great American Smokeout
Date:11/14/2007

Minnesotans successfully quit smoking, and encompass five different programs to help smokers quit.

QUITPLAN(R) Services for Minnesotans include:

* The QUITPLAN(R) Helpline -- The QUITPLAN Helpline offers telephone

counseling and free nicotine patches, lozenges or gum to eligible

callers.

* quitplan.com -- The website offers free lifetime membership, helpful

quitting tools and activities and the chance to connect online with

thousands of others who have chosen to quit tobacco.

* QUITPLAN(R) Centers -- QUITPLAN Centers provide in-person counseling in

a healthcare setting, as well as access to nicotine patches, lozenges or

gum.

* Community-Tailored QUITPLAN(R) Centers -- A combination of stop-smoking

tools and culturally-tailored counseling for communities of color.

* QUITPLAN(R) at Work -- The QUITPLAN at Work program offers free on-site

professional group counseling for eligible businesses with at least

eight employees ready to stop smoking.

About ClearWay Minnesota(SM)

ClearWay Minnesota is an independent, non-profit organization that improves the health of Minnesotans by reducing the harm caused by tobacco. ClearWay Minnesota serves Minnesota through its grant-making program, QUITPLAN(R) stop-smoking services and statewide outreach activities. It is funded with 3 percent of the state's 1998 tobacco settlement. For more information on ClearWay Minnesota or QUITPLAN Services, call 952-767-1400 or visit clearwaymn.org.

Contact: Mike Sheldon

Communications Manager

(952) 767-1425


'/>"/>
SOURCE ClearWay Minnesota
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Many Parents Share Genetic Test Findings With Kids
2. AWWA, National Association of Water and Sanitation of Mexico, Agree to Share Expertise and Resources for Improved Water Supply
3. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
4. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
5. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
6. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
7. United Medicorp, Inc.s Shareholders Approve All Proposals
8. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
9. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
10. Proxy Governance Joins ISS, Glass Lewis and Egan Jones in Recommending Arrow International Shareholders Vote to Approve the $45.50 Per Share Merger With Teleflex
11. Memry Corporation FY 2007 Revenues $51.7M; Net Income $317,000 or $0.01 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2010)... Taxes, Other Tobacco Prevention Initiatives , ... , , ... ... ... WASHINGTON , March 18 Kids in New Jersey will take center stage in the fight against tobacco on March ...
(Date:3/18/2010)... ... , , ... ... ... New Hampshire will take center stage in the fight against tobacco on March 24 as they join thousands of young people nationwide ...
(Date:3/18/2010)... President and CEO, Legacy(SM) , ... , , ... ... WASHINGTON , March ... ...
(Date:3/18/2010)... of U.S. medical students choosing internal medicine residencies ... significantly impact the shortage of primary care physicians. ... Program report, 2,722 U.S. seniors at medical schools ... 3.4 percent increase from 2,632 in 2009. The ... (2,660), 2007 (2,680), and 2006 (2,668). In comparison, ...
(Date:3/18/2010)... In its 21-year history, under the ... leaders, SRLA has trained more than 40,000 teenagers from ... area to complete the 26.2 mile Los Angeles Marathon. ... volunteer leaders will again participate in the LA Marathon. ... SRLA,s mission is to challenge at-risk secondary students to ...
Breaking Medicine News(10 mins):Health News:New Jersey Kids 'Kick Butts' on March 24 2Health News:New Jersey Kids 'Kick Butts' on March 24 3Health News:New Jersey Kids 'Kick Butts' on March 24 4Health News:New Jersey Kids 'Kick Butts' on March 24 5Health News:New Hampshire Kids 'Kick Butts' on March 24 2Health News:New Hampshire Kids 'Kick Butts' on March 24 3Health News:New Hampshire Kids 'Kick Butts' on March 24 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 2Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 3Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 5Health News:Residency match results not encouraging for adults needing primary care 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 2Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 3
... Services Program to Enhance Defense Medical,Logistics System, ... CAI ) announced today that it has ... million, to continue the company,s support,for the Defense ... Medical Logistics Functional Development Center (JMLFDC) at Fort,Detrick, ...
... Blood Bank Services: Revenue Up 77%, and Pending Spin-Off and Listing ... ... Strategic Investment: To Be Listed on NASDAQ, ... provider, Golden Meditech,Company Limited ("Golden Meditech" or "the Group", HKEx: 8180) today,announced the ...
... Bulletin Board: FTER) today announced that its board of ... in open market,transactions., "Our senior management has concluded ... the financial success of the company,including its exceptionally strong ... of Forterus., "We therefore believe that a small ...
... Group,Inc. (Amex: QGP ) (http://www.QuantumMD.com ), ... a scheduled presentation to be,delivered at Paulson Investment,s ... Guillama later this morning, announced today that,it has ... using the community,health systems (CHS) established by Quantum ...
... Nov. 12 Quigley Pharma Inc.,a wholly-owned subsidiary of ... the last subject in the Phase IIb Study is ... effectively move the,study to the final stage of data ... the patient information from,21 Study centers and conferring with ...
... improve health of school staff, SOUTH PORTLAND, Maine, ... districts will have an opportunity to participate in a,two-year ... improve,their overall health. The joint project of Anthem Blue ... Association Benefits Trust,and school districts based in Gardiner, Hampden, ...
Other Medicine News:Health News:CACI Awarded Three Contracts Worth $30 Million to Support Defense Medical Logistics Development 2Health News:CACI Awarded Three Contracts Worth $30 Million to Support Defense Medical Logistics Development 3Health News:CACI Awarded Three Contracts Worth $30 Million to Support Defense Medical Logistics Development 4Health News:Golden Meditech Releases FY2008/09 Interim Results 2Health News:Golden Meditech Releases FY2008/09 Interim Results 3Health News:Forterus Inc. Announces Stock Buyback 2Health News:The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 2Health News:The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 3Health News:The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 4Health News:Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter 2Health News:Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter 3Health News:Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter 4Health News:Innovative Wellness Project Launched in Four Maine School Districts 2
(Date:3/18/2010)... March 18 Poniard Pharmaceuticals, Inc. ... innovative oncology therapies, today announced that the U.S. Patent ... the composition of matter patent for picoplatin as RE41209, ... 2010 . The reissue was applied for May ... , the USPTO released the "Issue Notification" for the ...
(Date:3/18/2010)... , March 18 ... Chief Executive Officer, Pfizer, was elected board ... of America (PhRMA) today at the trade ... Chief Executive Officer Christopher Viehbacher ... Directors, and John C. Lechleiter , ...
(Date:3/18/2010)... results in too much ammonia in the blood. , ... , , ... ... (Logo: ... ...
Breaking Medicine Technology:U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 2U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 3U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 4U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 2Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 3Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 4Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 5Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 6Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 7Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 8FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 2FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 3FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 4FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 5Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 1Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 2Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 3Exposure to lead tobacco smoke raises risk of ADHD 10856 1Exposure to lead tobacco smoke raises risk of ADHD 10856 2Measuring and modeling blood flow in malaria 61892 1Measuring and modeling blood flow in malaria 61892 2
... & Johnson Pharmaceutical,Research & Development, L.L.C. (J&JPRD), ... (DORIBAX(TM), doripenem for injection), a,carbapenem antibiotic, was ... against certain,strains of Enterobacteriaceae, including Extended-spectrum Beta-lactamases,(ESBLs) ... is a large group of bacteria that ...
... Quality of Life and Lessened Fatigue According to ... College of Rheumatology (ACR) Annual Scientific Meeting, ... -- UCB announced,today results from several Phase III clinical ... (Tumor Necrosis Factor),- presented at the American College of ...
Other Medicine Technology:New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 2New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 3New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 4New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 5CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 2CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 3CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 4CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 5CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 6CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 7CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 8CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 9CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 10
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: